Key Developments: CorMedix Inc (CRMD.A)
0.93USD
18 Jun 2013
$0.08 (+9.42%)
$0.85
$0.89
$0.94
$0.89
19,636
6,975
$1.23
$0.16
Latest Key Developments (Source: Significant Developments)
CorMedix Inc Announces Changes in Executive Team
CorMedix Inc announced that it has made changes to its executive team as follows: Randy Milby has been promoted to Chief Executive Officer(CEO), effective January 1, 2013. Mr. Milby currently serves as Chief Operating Officer. Richard M. Cohen will serve as Chief Financial Officer(CFO), effective January 1, 2013, and will continue as Executive Chairman and director of CorMedix. Mr. Cohen currently is Interim CFO and Interim CEO. Full Article
CorMedix Inc. Announces FDA Designation For Neutrolin (CRMD003)
CorMedix Inc. announced that on September 15, 2011, the U.S. Food and Drug Administration (the FDA) advised CorMedix, that the Center for Drug Evaluation and Research (CDER) has been assigned as the lead agency for the pre-market review of Neutrolin. CorMedix will request a pre-Investigational New Drug (pre-IND" meeting with the FDA in preparation of filing an Investigational New Drug (IND) application. The FDA has 60 days to respond to the pre-IND meeting request. Once CorMedix submits an IND, the FDA has a statutory 30 days to review the IND submission. Once the FDA accepts CorMedix's IND, the Company can begin clinical studies. Full Article
CorMedix Inc. Announces Amended Agreement For CRMD001
CorMedix Inc. announced that it has amended its agreement with Shiva Biomedical, LLC. Under the amended license agreement, CorMedix and Shiva have mutually agreed to extend the development obligation milestone for the initiation of patient dosing in a phase III pivotal trial for CRMD001 from September 30, 2011 to March 31, 2012 and in addition enable the development of the diagnostic technology (CRMD002) independently of CRMD001. Additionally, the amendment extends and reallocates an existing $1 million milestone payment by the Company to Shiva upon the dosing of a patient in a phase III pivotal study. Now, under the terms of the amendment, the Company is obligated to pay Shiva $100,000 in September 2011, with additional payments of $450,000 to be made on or about December 31, 2011 and March 31, 2012, provided the Company elects to pursue the phase III pivotal development of CRMD001. As consideration for the extensions, the Company has granted Shiva a first security interest to the Company’s licensed intellectual property from Shiva. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
